The company’s board of directors has approved an investment of up to ₹533 crore for the project, which will be executed in a phased manner. The land has been allotted in the Industrial Area developed by DMIC Vikram Udyogpuri Ltd in Ujjain. The proposed facility will be a formulation manufacturing unit.
Third Quarter Results
Alkem Laboratories reported a 5% year-on-year rise in net profit at ₹626 crore in the December quarter. The company reported ₹595 crore profit in the corresponding quarter of the previous year. Revenue from operations was up marginally by 1.5% year-on-year to ₹3,374 crore in the quarter under review, as against ₹3,324 crore in the same quarter last year.
Also Read: Alkem Labs Q1 Results: Shares jump 7% after every parameter rises from last year
Earnings before interest, tax, depreciation, and amortisation or EBITDA climbed 7.4% to ₹759 crore, compared to ₹707.4 crore in the year-ago period. EBITDA margin expanded by 120 basis points to 22.5%, compared to 21.3% last year. For the first nine months of FY25, EBITDA margin stood at 21.6% as against FY25 guidance of 18.5-19%.
Overall contribution of the US sales to total sales stood at 19.1% in the quarter. During the quarter, the company received two approvals from the USFDA, including one tentative approval. Other international market sales contributed 9.8% to total sales in Q3FY25. The company has a presence mainly in Latin America, Australia and Europe.
Shares of Alkem Laboratories Ltd ended at ₹5,331.60, down by ₹2.50, or 0.047%, on the BSE.
Also Read: Alkem Labs shares slump over 8% despite record interim dividend
(Edited by : Jomy Jos Pullokaran)
